Acrivon Therapeutics, Inc. (ACRV) AI Dilution Summary

ACRV is funding itself through its at-the-market program: cash was $90,000,000 at 2026-06-30 against estimated monthly burn of $4,954,000. The ATM with Cowen and Company, LLC (TD Cowen), authorised to $100,000,000, sold 4,054,954 shares since the program began through 2026-06-30; ATM sales through 2026-06-30 are its most recent capital raised, and sales after that date are not yet reported.